Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I)

Inclusion Criteria: * AGHD male or female subjects * Stable GH replacement therapy for at least 3 months * Body Mass Index 18,5 to 35.0 kg/m2 * Achieved final height * Age ≥ 18 years Exclusion Criteria: * Known or suspected allergy to trial product or components of the trial product * Subjects with active malignancy * Severe cardiac insufficiency classified according to NYHA III-IV * Unstable angina pectoris, acute myocardial infarction within the last 12 months * Severe, uncontrolled hypertension: sitting blood pressure \> 180/110 mmHg * HbA1C \> 7,5 % * Impaired kidney function: plasma creatinine ≥ 150 umol/l according to the hospital lab. * Impaired liver function: liver parameters exceed 2 times or more the upper normal limit, according to the hospital lab. * Patients on insulin treatment * Stable pituitary replacement therapy for less than 3 months * Participation in any other clinical trial involving any investigational products within the last three months prior to this trial * Any diseases judged by the investigator that could affect the trial * Women of fertile age, who are pregnant, planning to become pregnant or breast-feeding. Women of fertile age, who are not currently using adequate contraception methods such as: contraceptive pills, IUD or who had not undergone hysterectomy or sterilization